LLY lilly.com: Rasio nilai perusahaan marang pendapatan

lilly.com (LLY) - logo korporat

The Eli Lilly and Company (LLY) portfolio dominates the metabolic disorder treatment segment driven by surging demand for obesity drugs. However, geopolitical instability and the risks of patent expiration abroad create certain challenges. The EV/Sales trend reflects market momentum, where 15216.83 determines this parameter level. Ultimate success depends on FDA approvals and the scaling of innovative drug production.

LLY Eli Lilly and Co.: Nilai perusahaan marang pendapatan ing interval 23.11.2025 - 20.11.2026

Eli Lilly and Co. - rincian analitis lan metrik utama (LLY)

- rega lan prakiraan konsensus rega:
- data kapitalisasi saham perusahaan:
- indikator dhuwit lan arus kas:
Analisis wiwitan perusahaan:lilly.com - LLY
Barang unggulan Eli Lilly & Co.

This indicator determines the market value of the business relative to its annual turnover, completely excluding the impact of debt load. The formula compares enterprise value (EV) with revenue, allowing for an assessment of real cash flow generation efficiency without distortions from financial leverage. By analyzing the EV/Sales multiple trajectory, an investor sees the steady growth of Eli Lilly and Company (LLY), supported by low geopolitical risks and the global protection of pharmaceutical assets.